Kerala Health Minister K Muraleedharan announced a sweeping overhaul of the state’s drug procurement framework on Saturday, directing officials to cut out middlemen and force pharmaceutical companies into direct tender participation. The directive seeks to guarantee patient access to quality branded medicines and shore up transparency within the Kerala Medical Services Corporation Ltd (KMSCL).
Eliminating Middlemen and Overhauling KMSCL Tenders
State health authorities are moving to reshape how public hospitals acquire pharmaceuticals. Minister Muraleedharan ordered that intermediaries be completely barred from entering KMSCL facilities or receiving any form of remuneration. Under the new rules, manufacturers must engage directly with the state tender process. Companies that currently charge high prices will face outright exclusion from future contracts.
At a review meeting held on Saturday, the minister instructed officials to resolve lingering medicine shortages in regional hospitals without delay.
Stricter Quality Benchmarks and Pricing Caps
According to the minister, eligible suppliers must have a track record of selling products to the government sector in at least two states. KMSCL will cap its acquisition costs: final purchase prices must stay lower than those paid by the in-house drug bank at Thiruvananthapuram Medical College Hospital. To enforce accountability, the state will publicly publish all accepted procurement prices on its official website.
Did you know? Under the newly announced guidelines, any supplier caught providing substandard medicines to KMSCL will face permanent blacklisting from government contracts. Additionally, it was found that several current suppliers manufacture drugs exclusively for the corporation.
Quality enforcement forms a core pillar of the overhaul. The state intends to permanently blacklist any pharmaceutical firm that delivers substandard medication to KMSCL, removing any possibility of future reinstatement for violating safety standards.
Procurement Timeline for Upcoming Fiscal Cycles
The state has established a strict calendar for upcoming medicine procurement cycles. Officials finalized a schedule at the Saturday review meeting requiring the tender process for the following year to open in October and wrap up by December. Under this timeline, successful bidders must complete the delivery of pharmaceuticals to state facilities by February 2027.
Frequently Asked Questions
Why is Kerala eliminating middlemen from drug procurement?
The state aims to increase transparency within KMSCL, lower acquisition costs, and ensure that public hospitals receive a steady supply of quality branded medicines.
What determines a pharmaceutical company’s eligibility to bid?
Companies must supply products to the government sector in at least two states and offer prices lower than those recorded at the Thiruvananthapuram Medical College Hospital in-house drug bank.
What happens if a company supplies substandard medication?
According to Health Minister K Muraleedharan, any firm supplying substandard drugs to KMSCL will be permanently blacklisted from the tender process.
When will the next round of medicines be supplied under this schedule?
Medicines from the upcoming tender cycle, which runs from October to December, are scheduled for supply by February 2027.
Stay Updated on Public Health Policy
Subscribe to our newsletter for the latest updates on healthcare administration, drug procurement reforms, and policy changes across the region.